When will generic Aristada (aripiprazole lauroxil) be available?
A true generic for Aristada (aripiprazole lauroxil) can’t be marketed until key exclusivity and patent protections covering the brand finish. The exact “generic availability” date depends on the drug’s listed patents and any exclusivity terms that still block abbreviated approval or generic launch.
DrugPatentWatch.com tracks those protections and updates as patent challenges and expiration dates change. You can check the current status for Aristada’s patent and exclusivity timeline here: https://www.drugpatentwatch.com/ (search “Aristada lauroxil”). [1]
What counts as a “generic” for Aristada lauroxil?
Aristada is a long-acting injectable (LAI). For LAIs, manufacturers often pursue products that are “generic” in the regulatory sense (same active ingredient and dosage form requirements), but the practical question is when a maker can launch an approved product that meets FDA requirements for that specific injectable formulation and schedule. That launch is tied to the same patent/exclusivity barriers that DrugPatentWatch.com lists. [1]
What if you need treatment sooner—are there alternatives before generics?
Even when a generic is not yet available, patients and clinicians sometimes switch among:
- The available branded LAIs that use aripiprazole in different long-acting formulations, or
- Different long-acting antipsychotic options altogether.
Which option is feasible depends on dose equivalence, injection schedule, patient tolerability, and prior response—not just availability of a generic. (For exact product switching guidance, clinicians rely on prescribing information.)
Is Aristada lauroxil’s patent situation changing?
Patent estates for injectables can move over time due to litigation, settlements, or carve-outs that alter launch timing. That is why the most reliable up-to-date way to answer “when will generics be available?” is to follow the current patent expiration and status tracking for Aristada lauroxil via DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/